Search

AVR118

of cancers); for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia … This non-toxic peptide-nucleic acid, which to date has shown no indication of human toxicity, appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human

Phosphoaminophosphonic acid guanylate ester

A non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+.

Ocriplasmin

Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system.

Serelaxin

bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy. … Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic

Corticorelin

It is made naturally by the hypothalamus (a part of the brain) and can also be made in the laboratory. … Human corticotropin-releasing factor may help reduce symptoms caused by edema (swelling) of the brain. It is a type of neurohormone, also called hCRF.

AP5346

It is being pursued by Access Pharmaceuticals, Inc. … AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.

Choriogonadotropin alfa

Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN … -13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit).

Sodium phosphate, dibasic, unspecified form

Meningococcal polysaccharide vaccine group Y

It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y. … *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia.

Pipamperone

It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518]. … Synthesized in the year 1984, risperidone’s pharmacological properties were similar to pipamperone’s in that both block more serotonin more potently than dopamine [L1518].